Lupin Gets US Regulator's Nod for Generic Ulcer Treatment Drug

New Delhi: Drug firm Lupin has received approval from the US Food and Drug Administration (FDA) to market generic Omeprazole delayed-release capsules, used to treat ulcer, in the American market.

The company said in a statement that it has received final approval for its Omeprazole delayed-release capsules (40 mg) from the US health regulator.

The Mumbai-based company's Omeprazole delayed-release capsules are the generic equivalent of AstraZeneca's Prilosec delayed-release capsules, which are indicated for the treatment of duodenal ulcer, gastric ulcer and gastro esophageal reflux disease (GERD).

The drug is also used for healing of erosive esophagitis and pathological hyper-secretory conditions.

According to IMS MAT June data, Prilosec had annual US sales of $185 million.

Shares in Lupin, on Thursday, ended nearly 5 per cent higher at Rs 1,898.50 apiece on the BSE.